Bristol Myers Squibb cancer drug flunks key test

The latest stories trending on MedCity News.

Editor's Pick

Top Story Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma Bristol Myers Squibb's Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial testing the regimen as an adjuvant therapy for patients whose melanoma has been surgically removed. While Opdualag is still projected to reach blockbuster status, it could face competition from a Regeneron Pharmaceuticals drug. Sponsored A Program That Fast Tracks the Development and Deployment of Digital Health Solutions Presented by Mayo Clinic Platform Mayo Clinic Platform_Solutions Studio seeks to help digital health companies accelerate the development and deployment of solutions into clinical workflows while providing transparency about solutions to hospitals. Mayo Clinic Platform developed their program to help digital health companies widen their reach and streamline commercialization. Learn more.

Featured News

Atria Health Launches National Partnership Model to Keep Cardiology Practices Independent Atria Health launched its partnership model for cardiology practices nationwide this week. Instead of buying and then subsequently owning practices, Atria provides capital, expertise and technology to help cardiologists build independent, physician-led practices. Midwest Health Purchasers Collaborative Taps Vida Health for Obesity Specialty Care Through a new partnership, members of the Midwest Health Purchasers Collaborative can access Vida Health's obesity care solutions. StartUPDATES: New Developments from Healthcare Startups Check out news from Oral Genome, Junevity, Coral, Keragon, and more. Remote Patient Monitoring Can Help Relieve Hospital Overcrowding — If Done Right Moving forward, it's essential for the health tech and medical fields to work together to make remote patient monitoring much more widely available and affordable for everyone across the country, with and without insurance.

Resources

Debunked | No-Fluff Healthcare News Show | Presented by MedCity News | Episode 12 Presented by MedCity News In the new episode of Debunked, we dive into the potential implications of Trump's reelection on healthcare policies. We break down the ongoing battle over the 340B drug discount program, including Johnson & Johnson's lawsuit against the federal government. Listen now

MedCity News • PO Box 901 • New York, NY unsubscribe